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Background: Studies have described illness associated with cystic ﬁbrosis (CF) early in life, but there is no comprehensive accounting of the
prevalence and ages of disease manifestation and progression described in individual studies.
Methods: We searched for peer-reviewed English-language studies of the health of children ≤6 years old with CF (published 1990–2014).
Structural abnormalities and dysfunction of the digestive and respiratory systems were summarized across relevant studies by system and age
group.
Results: Primary studies (125 total) from 22 countries described abnormalities, dysfunction, and disease progression in infancy and early
childhood. Improved health was consistently observed in association with diagnosis via newborn screening compared with cohorts diagnosed later
by symptomatic presentation.
Conclusions: The peer-reviewed literature is remarkably consistent: CF-associated growth impairment and airway abnormalities are reported at
birth, and disease progression is reported in infancy and throughout childhood. Earlier access to routine CF management is associated with
improved subsequent health status.
© 2015 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cystic fibrosis (CF) is a life-shortening, multisystem genetic
disease. Since the 1930s, the development and use of an arsenal
of symptomatic treatments and extensive prophylactic daily
treatment regimens have extended the CF median predicted
survival from just a few months following diagnosis to 38 years
of age for the cohort in the US CF Foundation Patient Registry
in the years 2008 to 2012 [1], and 34 to 44 years of age for the
cohort in the United Kingdom (UK) CF Registry in the years
2009 to 2013 [2]. Despite this dramatic improvement, CF
continues to be characterized by digestive and respiratory
dysfunction contributing to growth deficits, chronic respiratory
infection, progressive lung tissue damage, and premature death
[1]. The median age of death among individuals with CF
followed in the US and UK patient registries was 27 to 28 years
in 2012 [1,2].
The discovery of the mutated CF gene (cystic fibrosis
transmembrane conductance regulator; CFTR) in 1989 [3,4]
and the function of wild-type CFTR protein in 1992 [5]
established the underlying pathophysiology present in CF
epithelial tissues, including that of the sweat gland, the
pancreas, the airway, and the intestine. It is now recognized
that interventions targeting the underlying CFTR defect across
body systems have the potential to improve outcomes
throughout life for persons with CF. Because CF is a
progressive, multiorgan disease, initiation of symptomatic and
prophylactic treatments early in life with the help of newborn
screening has been shown to improve outcomes compared with
later initiation of treatment secondary to later diagnosis [6].
Similarly, it is likely that the initiation of interventions that
target the underlying CFTR defect before significant disease
progression has great potential to avoid accumulation of tissue
damage, allowing for better health maintenance and more
normal function for persons with CF. The optimal time for
initiation of treatments is dependent on when complications and
cumulative damage begin to occur in persons with CF.
It has long been appreciated that newborns with CF can have
serious pancreatic insufficiency and gastrointestinal complica-
tions related to their disease, as discussed in two recent reviews
[7,8]. In contrast, only fairly recently reviews [9–11] and
critical analyses [12,13] have begun to suggest that abnormal-
ities of the respiratory system consistent with early disease
progression can be observed early in life in children with CF.
To date, a comprehensive review of the ages of earliest disease
manifestation and progression across organ systems is lacking,
which represents a knowledge gap. Although it is understood
that disease progression will be unique to each individual, it is
important to establish the ages at which CF signs and symptomsmanifest and disease progression have been observed on a large
scale. Thus, we undertook a comprehensive review of published
primary studies of health, disease, and disease progression in the
respiratory and digestive systems reported for young children
with CF worldwide. We focused on the respiratory and digestive
systems because the major symptoms and causes of death are
associated with these two body systems [1].
The three research questions were: (1) At what ages have
CF-related dysfunction and structural differences been demon-
strated in young children with CF (≤6 years of age)? (2) At
what ages has disease progression been reported in young
children with CF? (3) At what ages are there improved
outcomes with early versus late treatment initiation in young
children with CF?2. Methods
2.1. Search details and dates
Three large literature databases (MEDLINE, CENTRAL,
and EMBASE) were searched between June and August 2014
for peer-reviewed, English-language, primary studies of the
health of young children (≤6 years of age) with CF. The search
strategy (Supplementary Material 1) was designed to capture a
broad range of study types to provide a comprehensive
summary of available results. Studies of treated and/or
untreated children with CF (all genotypes) published between
January 1, 1990 and August 6, 2014 were included. Studies
including a wider age range were included only if outcomes for
children aged 6 years or younger were analyzed separately
from outcomes for older groups. Reviews, systematic reviews,
meta-analyses, animal studies, studies of older persons only,
non–peer-reviewed publications, case studies, and treatment or
diagnosis guidelines were excluded.
Duplicate citations and articles of inappropriate types,
publication dates, and language were removed in a primary
sort. A secondary sorting of titles and abstracts eliminated
inappropriate study populations (non-CF, adults, older children,
parents) and in vitro studies. A single researcher conducted the
first two sorting phases. A final sorting of titles and abstracts
restricted the articles included to relevant studies of the
digestive and/or respiratory systems in young children (study
sample ages ≤6 years were determined from the title or
abstract of each study). Two researchers performed the final
sort independently and agreed on inclusion of each study, with
discrepancies resolved upon reading the full text. Two
researchers extracted data from each study independently
from each other.
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compared with outcomes for control populations without CF,
population norms (e.g., standard growth charts), baseline values for
study participants or between treatment groups (i.e., earlier versus
later treatment initiation). The purpose of this review was to
include a broad range of studies and study outcomes were
synthesized here in a non-statistical manner, due to the
heterogeneity of the study designs, outcome measures, and study
populations. Outcomes were summarized as worse or improved if
statistically significant differences were reported; outcomes that did
not reach statistical significance were summarized as not different.
3. Results
3.1. Search results
In all, 271 studies describing the health or illness of young
children with CF were drawn from an initial pool of 14,071
citations (including 3,310 duplicates). Of these, 125 were
identified as relevant studies of the CF digestive and/or
respiratory systems (Supplementary Fig. 1). A wide variety of
study designs, study sample sizes, and countries of origin were
represented in the included studies (Supplementary Table 1).
Study populations were from 22 countries in 8 major world
regions (North America; South America; Oceania; Western Asia;
and Western, Eastern, Northern, and Southern Europe) [14].
3.2. Summary of results
Literature exists for outcomes in children ≤6 years of age
relating to all three of the research questions for both the CF
digestive and respiratory systems. For Research Question 1 (At
what ages have CF-related dysfunction and structural differ-
ences been demonstrated in young children with CF [≤6 years
of age]?), there was a substantial evidence base for tissue
abnormalities and organ dysfunction in children prenatally,
from birth, and throughout early childhood to 6 years of age.
Abnormalities were observed at the molecular, cellular, tissue,
and organ levels, and manifested as large-scale physical signs
and symptoms. With respect to Research Question 2 (At what
ages has disease progression been reported in young children
with CF?), progression of disease in both the respiratory and
digestive systems was demonstrated in infants as young as
6 months of age, with significant respiratory structural and
functional decline occurring with each year of age in children
aged ≤6 years. Moreover, development of complications and
accumulation of damage were observed in young children,
including an increased risk of P. aeruginosa airway infection in
infancy (defined as up to 1 year of age in this review) and
potentially irreversible lung damage by 2 years of age. Finally,
for Research Question 3 (At what ages are there improved
outcomes with early versus late treatment initiation in young
children with CF?), a large evidence base demonstrated better
outcomes with earlier initiation of standard-of-care treatment as
a result of earlier diagnosis compared with later treatment
initiation due to later diagnosis. A difference in CF diagnosis
and associated treatment initiation of 4 to 13 months duringinfancy had a significant impact on outcomes throughout
childhood. Initiation of treatment and medical management
within 2 months from birth was associated with improved
outcomes in both the respiratory and digestive systems in
children ≤6 years of age.
3.3. CFTR expression and morbidity observed throughout early
childhood
In all, 5 articles studiedCFTR expression and function early in
life. Substantial prenatal CFTR mRNA expression was observed
in the pancreas, liver, gall bladder, and intestine, with somewhat
lower levels of expression in the trachea [15] and airways [16].
CFTR protein expression was also observed in prenatal
epithelium and glands of the intestine, as well as in the ciliated
cells, collecting ducts, and glands of airways. Immediately before
birth, CFTR protein expression was observed in the periphery of
acini of the airways [17], and CFTR mRNA was observed in
airway mucus-producing glands in infants and 2-year-olds [16].
Direct evidence of reduced CFTR function in young children
with CF included dysfunction of the cellular lining in the distal
bowel of 3-year-olds [18] and airways of 2-year-olds [19].
Structural abnormalities and dysfunction in the digestive and
respiratory systems were observed prenatally, in infants, and
throughout childhood among children with CF, including
bowel, pancreatic, and liver abnormalities, nutritional deficien-
cies, growth deficits, airway anomalies, inflammation, pulmo-
nary dysfunction, infection, and pulmonary exacerbations. A
total of 99 studies reported various abnormalities and
morbidities in children ≤6 years of age. These studies were
organized by similarities in reported outcomes and study
population ages, and the citations are listed in Table 1. A total
of 3 studies reported outcomes that were not different from
those in non-CF controls. The results of these studies are
described in the footnotes to Table 1.
Although the 99 studies listed in Table 1 identified significant
morbidity in the CF study populations, only a subset of these (41
total) also reported the proportion of the CF study population in
whom abnormalities and illness was observed. These proportions
of the study samples suffering morbidity are shown as individual
pie charts for these 41 studies in Fig. 1, organized by outcome and
age. Morbidity was observed in 50% or more of the study sample
for a majority of respiratory system outcomes (24/44 total). There
are more total outcomes than the number of articles because more
than one outcome was presented in some articles. Likewise,
morbidity was observed in 50% or more of the study sample for a
majority of digestive system outcomes (14/20 total). Many types of
abnormalities were observed in high proportions of children with
CF from infancy throughout early childhood. Specific measures of
morbidity varied among studies.
3.4. Progression of disease
The studies that document disease progression at the
youngest ages are summarized here and in Figs. 2 and 3.
Evidence of disease progression in both digestive and
respiratory systems of children with CF was observed by
Table 1
Types of abnormalities and morbidity observed in the respiratory and digestive systems of children ≤6 years of age with CF.
Prenatal
(no. of studies)
Infants a (no. of studies) Toddlers b (no. of studies) Preschoolers c (no. of studies)
Respiratory system
Airway lining and walls/mucus
coating abnormalities
2 [16,20] 6 [16,19–23] 5 [16,19,22–24] 2 [19,23]
Inflammation/immune response 1 [25] 7 [26–32] 5 [27,29,32–34] d 3 [29,32,33]
Poor chest-imaging scores e — 3 [30,35,36] 3 [35,37,38] 3 [35,37,38]
Bronchiectasis — 5 [30,39–42] 5 [37,38,40–42] 4 [37,38,40,41]
Airway wall thickening/smaller
luminal area
— 5 [22,30,40,43,44] 5 [22,38,40,43,44] 3 [38,40,43]
High airway resistance/mucus
plugging/obstruction
— 3 [40,45,46] 7 [37,38,40,45,47–49] 6 [37,38,40,47–49]
Air-trapping/hyperinflation — 8 [30,39,41,44,45,50–52] 7 [37,41,44,45,51–53] 2 [37,41]
Lung dysfunction f — 12 [44,50,52,54–62] 15 [44,47,52,54–56,58–60,62–67] 10 [47,55,56,62–65,67–69]
Perfusion deficits — 1 [40] 3 [38,40,70] 3 [38,40,70]
Infection g/colonization — 8 [30,56,71–76] 12 [34,36,47,56,70,72–78] 6 [47,56,70,72,74,75]
Abnormalities secondary to infectionh — 3 [40,74,79] i 4 [40,74,78,79] i 4 [40,74,79,80]
Pulmonary exacerbations — 3 [81–83] 3 [81–83] 3 [81–83]
Digestive system
Intestinal lining and walls/mucus
coating abnormalities
4 [20,84–86] 2 [20,86] 2 [18,87] 2 [18,87]
Inflammation — — 1 [87] 1 [87]
Pancreatic dysfunction — 9 [72,88–95] 7 [72,88,91–95] 1 [72]
Liver dysfunction — 2 [96,97] — —
Nutritional deficiencies j — 9 [88,90,96,98–103] 1 [98] —
Weight deficit k — 14 [50,51,58,59,61,88–90,95,104–108] 15 [51,58,59,63,64,70,95],
[104,106,108–113]
9 [63,64,70,104,106,108],
[110,112,113]
Height deficit — 12 [50,54,59,61,90,95],
[104–106,108,114,115] l
15 [54,59,63,64,95,104],
[106,108–115] l
9 [63,64,95,104,106,110],
[112–114]
a Infants: age range from 0 to b1 year old.
b Toddlers: age range from 1 to 3 years old.
c Preschoolers: age range from N3 to 6 years old.
d One study reported that exhaled nitric oxide (one type of immune response indicator) was not lower in 1-year-olds with CF than non-CF controls [116].
e Chest imaging methods include: X-ray, computed tomography, and magnetic resonance imaging.
f Lung function measures include: forced expiratory volume, forced expiratory flow, forced vital capacity, lung clearance index, maximal flow at functional
residual capacity, respiratory rate, and respiratory symptoms (cough and crackles).
g Includes both CF-related opportunistic bacterial infection and increased incidence of seasonal viral infection.
h Airway structural changes proposed by the individual study authors to be secondary to infection include: nasal polyps, bronchial surfactant composition alteration
and lung collapse, and reduced pulmonary tissue elasticity.
i The elastic properties of lung tissue (respiratory compliance) were reported to be normal at 41 to 97 weeks of age [117].
j Nutritional deficiencies included: Vitamins A, D, and E; essential fatty acids, protein, sodium, potassium, and zinc.
k Weight deficits included low body mass index.
l One study reported that height z-scores measured in children with CF between 0.12 and 2.5 years old were not different from those in non-CF controls [58].
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spirometry was observed in infants 6 months to 1 year of age
[58] (Fig. 2). While 59% to 71% of infants with CF were
determined to be pancreatic insufficient at birth, pancreatic
function declined in a subset of those determined to be pancreatic
sufficient at birth, such that an additional 16% to 20% were
insufficient by 6 months of age (Fig. 3) [88,90,95]. In addition,
airway viral and bacterial infection/colonization was observed in
children as young as 2 to 6 months of age [30,71] (Table 1),
including P. aeruginosa, a complication of CF.
Progression of disease continued throughout childhood,
including worsening of airway resistance [45], airway inflamma-
tion [78], air trapping [45,124], lung structure [35,40,43,123–126],
lung function (Fig. 2) [58,61,63,66,112,123], and nutrient
deficiencies [127,128]. Accumulation of lung damage was evident
by 1 year of age [36,123,124], and lung structure and function
worsened significantly each year of life in young children aged 0to 6 years [35,43,58,123,124]. One study, however, reported that
although 4 spirometric measures of lung function all worsened
between ages 0 to 5 years and 6 to 16 years, they worsened by a
significant amount from measures recorded in younger age groups
only at ages older than 16 years [40]. Another study reported a
worsening in lung clearance index in 33% of children between ages
3 to 5 years and 6 to 10 years, and improvement in 15% of
children over this same period [110], although there is a question as
to whether improvement in lung clearance index with age may be
an artifact of the changing ratio of lung volume to equipment dead
space volume with the growth of the lungs as the children aged
[129]. Respiratory structural abnormalities proposed by the
individual study authors to be secondary to infection including
nasal polyps [80], lung collapse [40,79], and reduced pulmonary
tissue elasticity [74] were evident within a few years of life
(Table 1), and “potentially irreversible” lung damage was evident
by 2 years of age [35]. One study reported that the pulmonary
Age (yrs)
0 1 2 3 4 5 6
Mean Age
Median Age
Mid-Range Age
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30
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34
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Pancreatic Dysfunction
Liver Dysfunction 
Nutritional Deficiencies
Weight Deficit
Height Deficit
Airway Inflammation
Poor Chest Score
Bronchiectasis
Bronchial Wall Thickening 
Obstruction
Air Trapping 
Lung Dysfunction
Perfusion Deficit
Airway Infection
Secondary Abnormalities
Pulmonary Exacerbations
Fig. 1. Percentage of study samples with morbidity. The shaded portion of each pie
chart corresponds to the percentage of the study sample with CF that was reported
to have specific morbidities or abnormalities. The sizes of the study samples with
CF ranged from 11 to 9895 (see Supplemental Table 1 for additional information
on study sample sizes). Numbers next to each pie chart are the study citation.
Mid-range age was calculated by subtracting the youngest age from the oldest age,
dividing by two, and adding the result to the youngest age.
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young children (with 0 to 1 year old as the reference age);
hospitalizations for pulmonary exacerbations increased from 64
total admissions among 168 infants aged 0 to 1 years to 86 hospital
admissions among 158 children aged 4 to 5 years [130]. In another
study, early respiratory symptoms (coughing, wheezing, rapid0 1 2 3 4 5 6 7
Aurora 2011
Ren 2014
Harrison 2009
Keller 2003
Walsh 2010
Kerby 2012
VanDevanter 2010
Konstan 2003
Kozlowska 2008
Linnane 2008
Pillarisetti 2011
Ranganathan 2004
Age (years)
Earliest documented decline
Dysfunction at study start
Fig. 2. Worsening of lung function in young children with CF. Twelve studies
documented within-patient longitudinal measures of lung function and all 12
reported decline [58,61,63,66,110,112,118–123]. Bars represent the age (mean,
median, or mid-range) at which lung function was first measured (study start) to
oldest age of follow-up (presented results truncated at 7 years). White triangles
represent the youngest documentation of within-patient worsening. Note: For each
study, lung function decline was observed at the youngest age of follow-up. Black
×s represent lung dysfunction (signs and symptoms, obstruction, or low spirometry
measures) compared with non-CF controls at study start.breathing) at 5 months of age were associated with greater
numbers of hospitalizations for respiratory illness by 17 months
of age [131].
Early signs of digestive system morbidity were associated with
subsequent poor respiratory outcomes and vice versa. Meconium
ileus at birth was a risk factor for bronchiectasis by 3 months of age
[42]. Low or high weight for age and height for age in 3-year-olds
predicted low or high spirometric lung function outcomes,
respectively, at 6 years of age [119,122]. In one study, pancreatic
insufficiency was associated with an increased hazard ratio for P.
aeruginosa airway infection starting at 2 months of age, with 62%
of children reported to have airway infection by 8 years of age
[72]. Pancreatic insufficiency was also associated with worse chest
X-ray scores and meconium ileus was associated with worse
spirometric lung function outcomes by 11 years of age [35].
Conversely, any occurrence of more serious hospital-managed
pulmonary exacerbation versus less serious home-managed
pulmonary exacerbation between ages 0 and 5 years was
associated with significantly lower weight at 5 years of age
[130]. A P. aeruginosa–positive culture at 4 years of age predicted
lower weight population norm percentile at 12 years of age [132].
One study, however, reported that better growth was observed by
age 18 months, specifically in infants with hyperinflation at
diagnosis, not those without hyperinflation or with pulmonary
obstruction [45].
3.5. Effects of early diagnosis and onset of treatment
In all, 12 studies compared health outcomes among children
diagnosed with CF with the help of newborn screening with
outcomes among those diagnosed as a result of symptom
presentation. The latter populations ranged from 4 to 24 months
of age before diagnosis, and were likely not systematically treated
with routine CF care until after diagnosis. In this context, routine
CF care included a variety of treatments and interventions
recommended for children with CF at the time and place of care,
including prophylactic and symptomatic nutritional and vitamin
supplements, high-calorie diets, pancreatic enzyme supplements,
chest physiotherapy, mucus thinners, anti-inflammatories, and
antibiotics. Most studies compared health outcomes associated
with initiation of routine CF care 12 to14 months earlier among
cohorts diagnosed by screening at about 1 month of age with
outcomes in cohorts diagnosed by symptom presentation at about
14 months of age.
In general, children with access to earlier routine CF care
secondary to earlier diagnosis had better outcomes compared
with those children whose access was later as a result of later
diagnosis. Benefits of earlier diagnosis included reduced airway
inflammation [133], improved lung structure [134], improved
lung function [95,133,135], delayed chronic airway infection
[134], lower incidence of mucoid P. aeruginosa colonization
[104], improved growth (Fig. 4) [95,104,106,111,133–138],
reduced hospitalizations [104,138], and improved survival
[133,136,139,140]. Of importance, these differences could not
be accounted for simply by greater inclusion of children with
less severe forms of CF in newborn screening cohorts, as they
were observed among children with identical CFTR genotypes,
50%
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Fig. 3. Pancreatic function variability. Six studies reported results indicating varying pancreatic status early in life; the results of these 6 studies are presented here
[88,90,92–95]. Data points represent the percentage of the study sample that were pancreatic insufficient at that age. Circles represent measurement of pancreatic
function using fecal elastase, squares represent measurement of pancreatic function using pancreatic isoamylase, fecal fat, pancreas stimulation, and/or symptoms, and
other symbols represent measurement of fecal fat. Note that the y-axis begins at 50%. Walkowiak (2005) was the single study of this group with a study sample
restricted to severe CFTR mutations [93]; other studies included a representative sample of genotypes. O’Sullivan 2013 reported that a subgroup of infants with CF
tested as pancreatic sufficient after having tested as pancreatic insufficient and vice versa. By 1 year old, 23% (3/13) of children were determined to be pancreatic
insufficient who were previously sufficient, and 8% (4/48) of children were determined to be pancreatic sufficient who were previously insufficient [92]. Pancreas
sufficiency or insufficiency was a result of the natural course of CF. The youngest measurement for Waters (1999) was the mid-range age of two group median
diagnosis ages and the oldest age was estimated from information given in the text.
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ileus (Supplementary Table 2, study and study sample character-
istics for Fig. 4).
Two studies compared cohorts of patients with mean ages of
diagnosis that were earlier by only 4 months (2 versus 6 months
of age). Chest X-ray scores at 5 years of age were not found to
differ between the groups [95], but lung function was improved
for the early diagnosis group between 5 and 10 years of age
[95,135] and weight and height were greater until age 5 years
[95]. In a third study, a 5 to 8 months earlier diagnosis (1 versus 6
to 9 months of age) was associated with a higher survival rate
(98% versus 88%) up to 16 years of age [136].
4. Discussion
During the first decades after CF was initially characterized,
infant mortality was dramatically reduced with the introduction
of pancreatic enzyme supplementation and greater attention to
early nutrition, as well as the coincident expansion of the0 2 4 6 8
Siret 2003
Collins 2008
Dankert-Roelse 1995 
Accurso 2005 
Mastella 2001 
Waters 1999 
Farrell 1997
Fig. 4. Improved weight with earlier versus later diagnosis and treatment initiation. Childr
did children diagnosed and treated later (squares). Arrows indicate the ages in each study
diagnosed later. Circles denote the age at which weights between the two groups were no
children. For 3 studies, weight was still significantly different between the two groups at the
with CF, and while these data represent improved weight, weight was not alway
[95,104,106,111,133,136,138]. The details of each study and study sample characteristicsavailability of antimicrobials to treat acute airway infection. Over
recent decades, the development and use of chronic and acute
therapies targeted at downstream CF symptoms and pathologies
have provided valuable reduction of symptoms for individuals
with demonstrable disease. Clinical trial outcomes characterizing
the clinical efficacy of pulmonary therapies, such as sustained
increases in pulmonary function or reduced risk of treatment with
intravenous antibiotics, have not translated well to very young
children with CF, however, primarily because spirometry
measures were not developed for and are not sensitive in early
CF disease [141]. As the use of these therapies has become more
common at younger ages, along with the introduction of several
prophylactic pulmonary treatments, a natural interest in earlier,
preventive intervention has led to the questions: (1) How early
does disease manifest and begin to progress for newborns with
CF, and (2) would earlier management of CF pathology translate
to improved health outcomes for persons with CF?
With regard to the question of the prevalence of CFTR
dysfunction in infants and children with CF, the peer-reviewed10 12 14 16 18 20 22
Age (years)
Earlier diagnosis group
Later diagnosis group
Greater weight with early diagnosis
No difference in weight between groups 
Study end (weight still greater)
en diagnosed and treated earlier (triangles) gained more weight over 5–20 years than
at which the children diagnosed earlier weighed significantly more than the children
longer significantly different, due to “catch-up growth” of the late-diagnosis group of
end of the study (black ×). Note: these comparisons were between groups of children
s improved to population norms with early diagnosis and treatment initiation
are provided in Supplementary Table 2.
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to growth deficits and airway pathologies from birth, is associated
with CF pathologies detectable in infancy, and results in
significant progression of respiratory disease with each year of
life in young children with CF. This conclusion should hardly be
surprising, as the pathologic ramifications of CFTR dysfunction
in the digestive system of infants with CF have been recognized
for more than half a century; the disease was named for pancreatic
autopsy findings in this population [142]. That pathologies
related to CFTR dysfunction are present at birth is irrefutable:
elevated concentrations of circulating immunoreactive trypsino-
gen secondary to CFTR dysfunction in the neonatal exocrine
pancreas are exploited for CF newborn screening, elevated sweat
chloride concentrations secondary to CFTR dysfunction in the
newborn sweat gland are diagnostic, and N10% of newborns
diagnosed with CF today present with meconium ileus and bowel
obstruction [1]. Further, the literature is remarkably consistent
with regard to observations of CF-associated growth impairment
and cumulative anatomical and functional airway abnormalities
beginning in infancy and progressing through childhood.
The implementation of CF newborn screening has provided a
means of examining whether or not earlier and more comprehen-
sive intervention in infants and young children with CF improves
health outcomes. Multiple studies have demonstrated growth
advantages in cohorts of children with CF identified with the help
of newborn screening when compared with cohorts diagnosed
from months to years later by symptom presentation. With the
exception of randomized controlled study designs, these compar-
isons are hampered by an obvious problem: children diagnosed on
the basis of symptom presentation are by definition symptomatic,
while a majority of infants diagnosed with the help of newborn
screening are not; thus, these groups are not necessarily
comparable with respect to the severity of underlying CFTR
dysfunction. Comparisons of contemporary cohorts of children
with identical CFTR genotypes, however, have demonstrated a
clear advantage with respect to height-for-age z-scores and
pulmonary function z-scores for children identified with the help
of newborn screening [143]. Given that earlier diagnosis translates
to earlier access to routine care provided by multidisciplinary CF
care teams, it follows that earlier intervention in infants is most
likely responsible for better health outcomes at an older age. Earlier
access to today’s rigorous multidisciplinary CF care, however, is
not sufficient to prevent cumulative anatomical and functional
changes observed in the airways of infants and young children with
CF and shortened lifespan. Our review confirms that underlying
CFTR dysfunction in infants and young children remains
associated with increased risk of mucus plugging, inhomogeneous
ventilation, reduced airflow, opportunistic bacterial infection, gas
trapping, bronchial wall thickening, pancreas and liver dysfunc-
tion, nutritional deficiencies, growth deficits, and increases in
concentration of cytokines and other inflammatory markers.
4.1. Limitations and possible biases
The purpose of this review was to include a wide range
of study types from researchers worldwide. The inclusion of
studies with many different study designs, sample populations,genotypes, diagnostic methods, outcome measures, and regions
of origin is a possible limitation, however. In consideration of
this limitation, the conclusions were maintained at a conserva-
tive level, and results were not subjected to meta-analysis.
An additional limitation is the possibility of Type II
statistical errors in studies of small sample size, due to the
relatively small number of children with CF. The large number
of studies reporting statistically significant differences despite
small sample sizes suggests that this limitation was negligible.
The large magnitude of the differences measured in children
with CF may account for the statistical significance reached
despite small study sample sizes.
As with any review based on published articles, there may
be publication bias in the studies available for review. For
instance, investigators may have a greater interest in publishing
(as well as an ability to publish) data demonstrating morbidity
in CF as opposed to data showing no difference between
affected and unaffected children, which could introduce bias. In
the same way, studies of interventions demonstrating resolution
of symptoms may be published at a greater rate than those
showing no effect, introducing bias.
Accepting these possible limitations, this literature survey
has identified a strikingly large number of studies describing
consistent structural and functional effects of reduced CFTR
expression in newborns, with progressive and cumulative
CF-related morbidity observed as children with CF age. Access
to today’s routine care from multidisciplinary teams, even
shortly after birth, appears insufficient to prevent inexorable
disease progression, suggesting that there is an opportunity
for improved health outcomes. Consistent observations of
CFTR dysfunction and CF disease progression in infancy and
early childhood suggest that careful evaluation of the potential
benefits of pharmacotherapies is warranted in these young
patients.
In conclusion, the peer-reviewed literature is remarkably
consistent regarding all three of our research questions. (1) At
what ages have CF-related dysfunction and structural differences
been demonstrated in young children with CF (≤6 years of age)?
CF-associated growth impairment and airway abnormalities are
reported at birth and the underlying pathology of CF directly
related to reduced CFTR protein function was demonstrated in
young children with CF. Abnormalities and dysfunction of the
digestive and respiratory systems were reported throughout early
childhood in CF. (2) At what ages has disease progression been
reported in young children with CF? Disease progression is
reported in infancy and throughout childhood. The youngest age
at which disease progression was reported was by the age of
6 months in both digestive (pancreatic sufficiency decline) and
respiratory systems (lung function decline). Accumulation of
lung damage was reported by 1 year of age, and lung structure
and function worsened significantly each year of life in young
children, with potentially irreversible lung damage reported by
the age of 2 years. (3) At what ages are there improved outcomes
with early versus late treatment initiation in young children with
CF? Earlier access to routine CF management improved
subsequent health status. Earlier diagnosis (by 4–14 months)
and standard-of-care treatment initiation in infancy compared
154 D.R. VanDevanter et al. / Journal of Cystic Fibrosis 15 (2016) 147–157with later diagnosis and subsequent treatment initiation improved
long-term outcomes, including survival.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2015.09.008.
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